User profiles for D. Bota
 | Daniela BotaUC Irvine Verified email at hs.uci.edu Cited by 6881 |
[HTML][HTML] Clinical practice experience with NovoTTF-100A™ system for glioblastoma: the Patient Registry Dataset (PRiDe)
…, DD Tran, Y Kew, R Cavaliere, JL Villano, DA Bota… - Seminars in …, 2014 - Elsevier
… Engelhard b , David Dinh Tran c , Yvonne Kew d , Robert Cavaliere e , John L. Villano f ,
Daniela Annenelie Bota g , Jeremy Rudnick h , Ashley Love Sumrall i , Jay-Jiguang Zhu j , …
Daniela Annenelie Bota g , Jeremy Rudnick h , Ashley Love Sumrall i , Jay-Jiguang Zhu j , …
Mitochondrial Lon protease in human disease and aging: Including an etiologic classification of Lon-related diseases and disorders
DA Bota, KJA Davies - Free Radical Biology and Medicine, 2016 - Elsevier
The Mitochondrial Lon protease, also called LonP1 is a product of the nuclear gene LONP1.
Lon is a major regulator of mitochondrial metabolism and response to free radical damage, …
Lon is a major regulator of mitochondrial metabolism and response to free radical damage, …
Interstitial chemotherapy with biodegradable BCNU (Gliadel®) wafers in the treatment of malignant gliomas
DA Bota, A Desjardins, JA Quinn… - … and clinical risk …, 2007 - Taylor & Francis
Malignant gliomas represent the majority of primary brain tumors, and the prognosis of the
patients afflicted with these tumors has been historically dismal, with almost uniform …
patients afflicted with these tumors has been historically dismal, with almost uniform …
Serial evaluation of the SOFA score to predict outcome in critically ill patients
FL Ferreira, DP Bota, A Bross, C Mélot, JL Vincent - Jama, 2001 - jamanetwork.com
ContextEvaluation of trends in organ dysfunction in critically ill patients may help predict
outcome.ObjectiveTo determine the usefulness of repeated measurement the Sequential Organ …
outcome.ObjectiveTo determine the usefulness of repeated measurement the Sequential Organ …
Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 …
Background Rindopepimut (also known as CDX-110), a vaccine targeting the EGFR deletion
mutation EGFRvIII, consists of an EGFRvIII-specific peptide conjugated to keyhole limpet …
mutation EGFRvIII, consists of an EGFRvIII-specific peptide conjugated to keyhole limpet …
Association of autologous tumor lysate-loaded dendritic cell vaccination with extension of survival among patients with newly diagnosed and recurrent glioblastoma: a …
…, R Chaudhary, SA Goldlust, IY Lee, DA Bota… - JAMA …, 2023 - jamanetwork.com
Importance Glioblastoma is the most lethal primary brain cancer. Clinical outcomes for
glioblastoma remain poor, and new treatments are needed. Objective To investigate whether …
glioblastoma remain poor, and new treatments are needed. Objective To investigate whether …
[HTML][HTML] First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma
Background Standard therapy for glioblastoma includes surgery, radiotherapy, and
temozolomide. This Phase 3 trial evaluates the addition of an autologous tumor lysate-pulsed …
temozolomide. This Phase 3 trial evaluates the addition of an autologous tumor lysate-pulsed …
C-reactive protein levels correlate with mortality and organ failure in critically ill patients
SMA Lobo, FRM Lobo, DP Bota, F Lopes-Ferreira… - Chest, 2003 - Elsevier
Study objectives C-reactive protein (CRP) is an acute-phase protein, the blood levels of which
increase rapidly in response to infection, trauma, ischemia, burns, and other inflammatory …
increase rapidly in response to infection, trauma, ischemia, burns, and other inflammatory …
[HTML][HTML] BRAF–MEK inhibition in newly diagnosed papillary craniopharyngiomas
Background Craniopharyngiomas, primary brain tumors of the pituitary–hypothalamic axis,
can cause clinically significant sequelae. Treatment with the use of surgery, radiation, or both …
can cause clinically significant sequelae. Treatment with the use of surgery, radiation, or both …
Lon protease preferentially degrades oxidized mitochondrial aconitase by an ATP-stimulated mechanism
DA Bota, KJA Davies - Nature cell biology, 2002 - nature.com
… or to a control morpholino oligonucleotide for 0–4 d. Total aconitase protein was visualized
using a … , 2 and 4 d after treatment with morpholino oligonucleotides. d, Aconitase activity was …
using a … , 2 and 4 d after treatment with morpholino oligonucleotides. d, Aconitase activity was …